BioNTech-话题@MedSci

#BioNTech#

44篇内容 | 2608人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1391185, encodeId=6f271391185dc, content=<a href='/topic/show?id=9c5e34585a' target=_blank style='color:#2F92EE;'>#BioNTech#</a>, objectTitle=BioNTech新冠mRNA疫苗或将7月前在中国获批，多款国外疫苗引入疫苗进展缓慢, objectType=article, longId=210641, objectId=38522106413a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=38522106413a, replyNumber=0, likeNumber=61, createdTime=2021-05-01, rootId=0, userName=124987cdm26暂无昵称, userId=e3fb2500073, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=38522106413a, moduleTitle=BioNTech新冠mRNA疫苗或将7月前在中国获批，多款国外疫苗引入疫苗进展缓慢, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=38522106413a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1391184, encodeId=989c1391184ce, content=<a href='/topic/show?id=9c5e34585a' target=_blank style='color:#2F92EE;'>#BioNTech#</a>, objectTitle=辉瑞/BioNTech新冠疫苗保护期6个月有效率仍达91.3%, objectType=article, longId=209343, objectId=5e5c20934309, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5e5c20934309, replyNumber=0, likeNumber=78, createdTime=2021-04-03, rootId=0, userName=124987cdm26暂无昵称, userId=e3fb2500073, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5e5c20934309, moduleTitle=辉瑞/BioNTech新冠疫苗保护期6个月有效率仍达91.3%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5e5c20934309)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1391183, encodeId=8c901391183db, content=<a href='/topic/show?id=9c5e34585a' target=_blank style='color:#2F92EE;'>#BioNTech#</a>, objectTitle=因包装问题，香港暂停接种BioNTech疫苗, objectType=article, longId=208956, objectId=9c732089568a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c732089568a, replyNumber=0, likeNumber=55, createdTime=2021-03-26, rootId=0, userName=124987cdm26暂无昵称, userId=e3fb2500073, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c732089568a, moduleTitle=因包装问题，香港暂停接种BioNTech疫苗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c732089568a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1391182, encodeId=4c7413911826f, content=<a href='/topic/show?id=9c5e34585a' target=_blank style='color:#2F92EE;'>#BioNTech#</a>, objectTitle=MMWR：Pfizer-BioNTech疫苗在疗养院人群中，疗效显著！, objectType=article, longId=208554, objectId=f0e9208554fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f0e9208554fe, replyNumber=0, likeNumber=57, createdTime=2021-03-19, rootId=0, userName=124987cdm26暂无昵称, userId=e3fb2500073, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f0e9208554fe, moduleTitle=MMWR：Pfizer-BioNTech疫苗在疗养院人群中，疗效显著！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f0e9208554fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1391181, encodeId=29a61391181ef, content=<a href='/topic/show?id=9c5e34585a' target=_blank style='color:#2F92EE;'>#BioNTech#</a>, objectTitle=辉瑞/ BioNTech COVID-19疫苗的真实世界证据, objectType=article, longId=208451, objectId=1d6420845140, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d6420845140, replyNumber=0, likeNumber=75, createdTime=2021-03-17, rootId=0, userName=124987cdm26暂无昵称, userId=e3fb2500073, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d6420845140, moduleTitle=辉瑞/ BioNTech COVID-19疫苗的真实世界证据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d6420845140)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1391180, encodeId=721c139118073, content=<a href='/topic/show?id=9c5e34585a' target=_blank style='color:#2F92EE;'>#BioNTech#</a>, objectTitle=辉瑞/BioNTech疫苗可中和巴西新冠病毒变种, objectType=article, longId=208209, objectId=afc92082093c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=afc92082093c, replyNumber=0, likeNumber=71, createdTime=2021-03-11, rootId=0, userName=124987cdm26暂无昵称, userId=e3fb2500073, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=afc92082093c, moduleTitle=辉瑞/BioNTech疫苗可中和巴西新冠病毒变种, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=afc92082093c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1391179, encodeId=031713911e945, content=<a href='/topic/show?id=9c5e34585a' target=_blank style='color:#2F92EE;'>#BioNTech#</a>, objectTitle=以色列全新真实世界研究证实BioNTech疫苗在首剂后有效率为85％，力证推迟接种二剂, objectType=article, longId=207323, objectId=970820e3233e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=970820e3233e, replyNumber=0, likeNumber=69, createdTime=2021-02-21, rootId=0, userName=124987cdm26暂无昵称, userId=e3fb2500073, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=970820e3233e, moduleTitle=以色列全新真实世界研究证实BioNTech疫苗在首剂后有效率为85％，力证推迟接种二剂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=970820e3233e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1391178, encodeId=eef313911e8d2, content=<a href='/topic/show?id=9c5e34585a' target=_blank style='color:#2F92EE;'>#BioNTech#</a>, objectTitle=赛诺菲首席执行官：将生产1亿剂辉瑞BioNTech新冠疫苗, objectType=article, longId=206418, objectId=9df620641827, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9df620641827, replyNumber=0, likeNumber=59, createdTime=2021-01-31, rootId=0, userName=124987cdm26暂无昵称, userId=e3fb2500073, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9df620641827, moduleTitle=赛诺菲首席执行官：将生产1亿剂辉瑞BioNTech新冠疫苗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9df620641827)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1391177, encodeId=bfac13911e7df, content=<a href='/topic/show?id=9c5e34585a' target=_blank style='color:#2F92EE;'>#BioNTech#</a>, objectTitle=药监局已批准新冠疫苗Ⅱ期临床，BioNTech明年供应至少1亿剂, objectType=article, longId=205615, objectId=cdcb20561580, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cdcb20561580, replyNumber=0, likeNumber=68, createdTime=2021-01-12, rootId=0, userName=124987cdm26暂无昵称, userId=e3fb2500073, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cdcb20561580, moduleTitle=药监局已批准新冠疫苗Ⅱ期临床，BioNTech明年供应至少1亿剂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cdcb20561580)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1391176, encodeId=d1c013911e6ea, content=<a href='/topic/show?id=9c5e34585a' target=_blank style='color:#2F92EE;'>#BioNTech#</a>, objectTitle=辉瑞和BioNTech将额外向欧盟提供1亿支COVID-19疫苗（COMIRNATY）, objectType=article, longId=205039, objectId=f591205039cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f591205039cf, replyNumber=0, likeNumber=90, createdTime=2021-01-01, rootId=0, userName=124987cdm26暂无昵称, userId=e3fb2500073, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f591205039cf, moduleTitle=辉瑞和BioNTech将额外向欧盟提供1亿支COVID-19疫苗（COMIRNATY）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f591205039cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1391175, encodeId=2d6c13911e57f, content=<a href='/topic/show?id=9c5e34585a' target=_blank style='color:#2F92EE;'>#BioNTech#</a>, objectTitle=NEJM：辉瑞/BioNTech新冠mRNA疫苗有效率为95%！FDA将紧急应用授权, objectType=article, longId=204415, objectId=8ae32044156a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ae32044156a, replyNumber=0, likeNumber=62, createdTime=2020-12-13, rootId=0, userName=124987cdm26暂无昵称, userId=e3fb2500073, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ae32044156a, moduleTitle=NEJM：辉瑞/BioNTech新冠mRNA疫苗有效率为95%！FDA将紧急应用授权, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8ae32044156a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1391174, encodeId=20a413911e41d, content=<a href='/topic/show?id=9c5e34585a' target=_blank style='color:#2F92EE;'>#BioNTech#</a>, objectTitle=年底前或将打上疫苗？辉瑞和BioNTech向FDA提交申请, objectType=article, longId=204193, objectId=34e920419394, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=34e920419394, replyNumber=0, likeNumber=90, createdTime=2020-12-07, rootId=0, userName=124987cdm26暂无昵称, userId=e3fb2500073, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=34e920419394, moduleTitle=年底前或将打上疫苗？辉瑞和BioNTech向FDA提交申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=34e920419394)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1391173, encodeId=2da313911e3c3, content=<a href='/topic/show?id=9c5e34585a' target=_blank style='color:#2F92EE;'>#BioNTech#</a>, objectTitle=英国授权辉瑞/ BioNTech研发的新冠疫苗全面使用, objectType=article, longId=204055, objectId=0d39204055c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0d39204055c5, replyNumber=0, likeNumber=97, createdTime=2020-12-04, rootId=0, userName=124987cdm26暂无昵称, userId=e3fb2500073, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0d39204055c5, moduleTitle=英国授权辉瑞/ BioNTech研发的新冠疫苗全面使用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0d39204055c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1391172, encodeId=3dfb13911e254, content=<a href='/topic/show?id=9c5e34585a' target=_blank style='color:#2F92EE;'>#BioNTech#</a>, objectTitle=新冠大流行转折点？辉瑞，BioNTech正式向美国FDA提交申请以批准新冠疫苗, objectType=article, longId=203593, objectId=90be20359388, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=90be20359388, replyNumber=0, likeNumber=65, createdTime=2020-11-22, rootId=0, userName=124987cdm26暂无昵称, userId=e3fb2500073, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=90be20359388, moduleTitle=新冠大流行转折点？辉瑞，BioNTech正式向美国FDA提交申请以批准新冠疫苗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=90be20359388)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1391171, encodeId=d31613911e179, content=<a href='/topic/show?id=9c5e34585a' target=_blank style='color:#2F92EE;'>#BioNTech#</a>, objectTitle=重大突破：辉瑞和BioNTech研发的新冠疫苗90％有效, objectType=article, longId=203207, objectId=0b4920320e19, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b4920320e19, replyNumber=0, likeNumber=91, createdTime=2020-11-11, rootId=0, userName=124987cdm26暂无昵称, userId=e3fb2500073, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b4920320e19, moduleTitle=重大突破：辉瑞和BioNTech研发的新冠疫苗90％有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b4920320e19)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1391170, encodeId=228213911e017, content=<a href='/topic/show?id=9c5e34585a' target=_blank style='color:#2F92EE;'>#BioNTech#</a>, objectTitle=辉瑞加拿大公司和BioNTech开始向加拿大卫生部提交SARS-CoV-2疫苗候选BNT162b2的滚动申请, objectType=article, longId=201927, objectId=300020192e1c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=300020192e1c, replyNumber=0, likeNumber=71, createdTime=2020-10-12, rootId=0, userName=124987cdm26暂无昵称, userId=e3fb2500073, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=300020192e1c, moduleTitle=辉瑞加拿大公司和BioNTech开始向加拿大卫生部提交SARS-CoV-2疫苗候选BNT162b2的滚动申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=300020192e1c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1391169, encodeId=014513911697b, content=<a href='/topic/show?id=9c5e34585a' target=_blank style='color:#2F92EE;'>#BioNTech#</a>, objectTitle=BioNTech/辉瑞向欧盟提交COVID-19疫苗滚动上市申请, objectType=article, longId=201861, objectId=ef3f20186143, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ef3f20186143, replyNumber=0, likeNumber=62, createdTime=2020-10-10, rootId=0, userName=124987cdm26暂无昵称, userId=e3fb2500073, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ef3f20186143, moduleTitle=BioNTech/辉瑞向欧盟提交COVID-19疫苗滚动上市申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ef3f20186143)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1391168, encodeId=395e139116874, content=<a href='/topic/show?id=9c5e34585a' target=_blank style='color:#2F92EE;'>#BioNTech#</a>, objectTitle=辉瑞与BioNTech：三期临床试验规模扩大，最终结果10月底见分晓, objectType=article, longId=200679, objectId=181a2006e961, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=181a2006e961, replyNumber=0, likeNumber=105, createdTime=2020-09-16, rootId=0, userName=124987cdm26暂无昵称, userId=e3fb2500073, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=181a2006e961, moduleTitle=辉瑞与BioNTech：三期临床试验规模扩大，最终结果10月底见分晓, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=181a2006e961)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1391167, encodeId=afab139116ee9, content=<a href='/topic/show?id=9c5e34585a' target=_blank style='color:#2F92EE;'>#BioNTech#</a>, objectTitle=康希诺生物的新冠疫苗在中期研究中显示出良好的前景；英国从Pfizer / BioNTech和Valneva将获得9000万剂可能的COVID-19疫苗, objectType=article, longId=197841, objectId=90a319e841cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=90a319e841cf, replyNumber=0, likeNumber=80, createdTime=2020-07-22, rootId=0, userName=124987cdm26暂无昵称, userId=e3fb2500073, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=90a319e841cf, moduleTitle=康希诺生物的新冠疫苗在中期研究中显示出良好的前景；英国从Pfizer / BioNTech和Valneva将获得9000万剂可能的COVID-19疫苗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=90a319e841cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1391166, encodeId=64711391166cc, content=<a href='/topic/show?id=9c5e34585a' target=_blank style='color:#2F92EE;'>#BioNTech#</a>, objectTitle=两款新冠病毒疫苗获批临床试验BioNTech/辉瑞mRNA疫苗和津大学腺病毒疫苗, objectType=article, longId=192847, objectId=447019284ed3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=447019284ed3, replyNumber=0, likeNumber=83, createdTime=2020-04-25, rootId=0, userName=124987cdm26暂无昵称, userId=e3fb2500073, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=447019284ed3, moduleTitle=两款新冠病毒疫苗获批临床试验BioNTech/辉瑞mRNA疫苗和津大学腺病毒疫苗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=447019284ed3)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

BioNTech

2020-05-29

124987cdm26暂无昵称 (审核中...)

前往app查看评论内容

#BioNTech#

BioNTech新冠mRNA疫苗或将7月前在中国获批，多款国外疫苗引入疫苗进展缓慢

2021-05-01

124987cdm26暂无昵称 (审核中...)

前往app查看评论内容

#BioNTech#

辉瑞/BioNTech新冠疫苗保护期6个月有效率仍达91.3%

2021-04-03

124987cdm26暂无昵称 (审核中...)

前往app查看评论内容

#BioNTech#

因包装问题，香港暂停接种BioNTech疫苗

2021-03-26

124987cdm26暂无昵称 (审核中...)

前往app查看评论内容

#BioNTech#

MMWR：Pfizer-BioNTech疫苗在疗养院人群中，疗效显著！

2021-03-19

124987cdm26暂无昵称 (审核中...)

前往app查看评论内容

#BioNTech#

辉瑞/ BioNTech COVID-19疫苗的真实世界证据

2021-03-17

124987cdm26暂无昵称 (审核中...)

前往app查看评论内容

#BioNTech#

辉瑞/BioNTech疫苗可中和巴西新冠病毒变种

2021-03-11

124987cdm26暂无昵称 (审核中...)

前往app查看评论内容

#BioNTech#

以色列全新真实世界研究证实BioNTech疫苗在首剂后有效率为85％，力证推迟接种二剂

2021-02-21

124987cdm26暂无昵称 (审核中...)

前往app查看评论内容

#BioNTech#

赛诺菲首席执行官：将生产1亿剂辉瑞BioNTech新冠疫苗

2021-01-31

124987cdm26暂无昵称 (审核中...)

前往app查看评论内容

#BioNTech#

药监局已批准新冠疫苗Ⅱ期临床，BioNTech明年供应至少1亿剂

2021-01-12

124987cdm26暂无昵称 (审核中...)

前往app查看评论内容

#BioNTech#

辉瑞和BioNTech将额外向欧盟提供1亿支COVID-19疫苗（COMIRNATY）

2021-01-01

124987cdm26暂无昵称 (审核中...)

前往app查看评论内容

#BioNTech#

NEJM：辉瑞/BioNTech新冠mRNA疫苗有效率为95%！FDA将紧急应用授权

2020-12-13

124987cdm26暂无昵称 (审核中...)

前往app查看评论内容

#BioNTech#

年底前或将打上疫苗？辉瑞和BioNTech向FDA提交申请

2020-12-07

124987cdm26暂无昵称 (审核中...)

前往app查看评论内容

#BioNTech#

英国授权辉瑞/ BioNTech研发的新冠疫苗全面使用

2020-12-04

124987cdm26暂无昵称 (审核中...)

前往app查看评论内容

#BioNTech#

新冠大流行转折点？辉瑞，BioNTech正式向美国FDA提交申请以批准新冠疫苗

2020-11-22

124987cdm26暂无昵称 (审核中...)

前往app查看评论内容

#BioNTech#

重大突破：辉瑞和BioNTech研发的新冠疫苗90％有效

2020-11-11

124987cdm26暂无昵称 (审核中...)

前往app查看评论内容

#BioNTech#

辉瑞加拿大公司和BioNTech开始向加拿大卫生部提交SARS-CoV-2疫苗候选BNT162b2的滚动申请

2020-10-12

124987cdm26暂无昵称 (审核中...)

前往app查看评论内容

#BioNTech#

BioNTech/辉瑞向欧盟提交COVID-19疫苗滚动上市申请

2020-10-10

124987cdm26暂无昵称 (审核中...)

前往app查看评论内容

#BioNTech#

辉瑞与BioNTech：三期临床试验规模扩大，最终结果10月底见分晓

2020-09-16

124987cdm26暂无昵称 (审核中...)

前往app查看评论内容

#BioNTech#

康希诺生物的新冠疫苗在中期研究中显示出良好的前景；英国从Pfizer / BioNTech和Valneva将获得9000万剂可能的COVID-19疫苗

2020-07-22

124987cdm26暂无昵称 (审核中...)

前往app查看评论内容

#BioNTech#

两款新冠病毒疫苗获批临床试验BioNTech/辉瑞mRNA疫苗和津大学腺病毒疫苗

2020-04-25

科室
- - 订阅+
  - 更多科室
工具
服务